General Information of Drug Combination (ID: DCMYOIZ)

Drug Combination Name
BIO-300 Bendamustine hydrochloride
Indication
Disease Entry Status REF
Adult T acute lymphoblastic leukemia Investigative [1]
Component Drugs BIO-300   DMJ7NVI Bendamustine hydrochloride   DMFH15Z
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: MOLT-4
Zero Interaction Potency (ZIP) Score: 3.74
Bliss Independence Score: 3.02
Loewe Additivity Score: 1.75
LHighest Single Agent (HSA) Score: 4.45

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]
Indication(s) of Bendamustine hydrochloride
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Approved [4]
Bendamustine hydrochloride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [4]
------------------------------------------------------------------------------------
Bendamustine hydrochloride Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Bendamustine hydrochloride Interacts with 13 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [5]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [5]
Beta-galactosidase (GLB1) OTB0TKAG BGAL_HUMAN Increases Expression [7]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [5]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [5]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [5]
Caspase-6 (CASP6) OTXLD3EC CASP6_HUMAN Increases Activity [5]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [5]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [8]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [5]
PRKC apoptosis WT1 regulator protein (PAWR) OTKY7W52 PAWR_HUMAN Decreases Expression [5]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Increases Localization [5]
Death domain-associated protein 6 (DAXX) OTX6O7PL DAXX_HUMAN Decreases Expression [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Anaplastic large cell lymphoma DC8J3L7 SR Investigative [1]
Astrocytoma DC03HBQ SNB-19 Investigative [1]
Childhood T acute lymphoblastic leukemia DCD71RM CCRF-CEM Investigative [1]
Chronic myelogenous leukemia DCT6R7A K-562 Investigative [1]
Glioma DC7RL2B SF-539 Investigative [1]
Glioma DCPD8LK SF-268 Investigative [1]
Papillary renal cell carcinoma DCLWPYT ACHN Investigative [1]
Plasma cell myeloma DCDD94C RPMI-8226 Investigative [1]
Renal cell carcinoma DCZBXNF UO-31 Investigative [1]
Breast adenocarcinoma DC6LYSZ MDA-MB-468 Investigative [9]
Carcinoma DCKAVL0 RXF 393 Investigative [9]
Colon adenocarcinoma DC695SI COLO 205 Investigative [9]
Invasive ductal carcinoma DCWD8MG HS 578T Investigative [9]
Invasive ductal carcinoma DCTPF96 BT-549 Investigative [9]
Adenocarcinoma DCUUA2Q DU-145 Investigative [10]
Adenocarcinoma DCPSVKC OVCAR3 Investigative [10]
Adenocarcinoma DCTI5RQ NCIH23 Investigative [10]
Adenocarcinoma DC6BYV9 A549 Investigative [10]
Adenocarcinoma DCP9C07 SW-620 Investigative [10]
Adenocarcinoma DCRXGG7 HCT116 Investigative [10]
Adenocarcinoma DCCIQPG HCC-2998 Investigative [10]
Adenocarcinoma DC9PG7A HCT-15 Investigative [10]
Adenocarcinoma DCYUDI0 HT29 Investigative [10]
Cutaneous melanoma DCZGLTG SK-MEL-28 Investigative [10]
High grade ovarian serous adenocarcinoma DCEHGSK OVCAR-5 Investigative [10]
High grade ovarian serous adenocarcinoma DC7UDR7 OVCAR-4 Investigative [10]
High grade ovarian serous adenocarcinoma DCR1YRN OVCAR-8 Investigative [10]
Large cell lung carcinoma DCBZVS8 NCI-H460 Investigative [10]
Lung adenocarcinoma DCZIBN3 NCI-H522 Investigative [10]
Melanoma DCKW0CO MALME-3M Investigative [10]
Minimally invasive lung adenocarcinoma DCIADZT NCI-H322M Investigative [10]
Prostate carcinoma DCNSDSE PC-3 Investigative [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 32 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
5 Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol. 2003 Sep 1;66(5):711-24. doi: 10.1016/s0006-2952(03)00410-6.
6 Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54.
7 Chronic senescent human mesenchymal stem cells as possible contributor to the wound healing disorder after exposure to the alkylating agent sulfur mustard. Arch Toxicol. 2021 Feb;95(2):727-747. doi: 10.1007/s00204-020-02946-5. Epub 2021 Jan 25.
8 Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma. 2004 Jul;45(7):1429-36. doi: 10.1080/1042819042000198858.
9 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
10 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.